medcelerator · clinician one-pager
New Prescription Ointment for Mild-to-Moderate Eczema Ages 2 and Up
Adquey (difamilast) — topical ointment for mild-to-moderate eczema (atopic dermatitis)
FDA Approved · United States · September 22, 2026
Condition: Atopic Dermatitis
Who this is for
This is for people with mild to moderate atopic dermatitis (eczema) — and caregivers of children 2 years and older — who may be candidates for labelled US Adquey ointment. It explains the 12 Feb 2026 FDA approval, how twice-daily topical use works, Week-4 clearance numbers from the label, how Adquey relates to (and is distinct from) older topical PDE4 ointment, and how to ask a dermatologist or paediatrician for a prescription — without treating Adquey as a steroid, confusing it with injectable biologics for severe disease, or importing a US or Japanese tube. Authorised is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219474Orig1s000lbl.pdf
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/adquey-difamilast-atopic-dermatitis